James McArthur, PepGen president and CEO (via PepGen)
June 14, 2023 02:45 PM EDT
Pharma

Pep­Gen de­lays PhI study on my­oton­ic dy­s­tro­phy as it awaits more in­fo on clin­i­cal hold

Katherine Lewin

News Reporter

Pep­Gen is no longer mov­ing ahead with a Phase I study for its can­di­date for my­oton­ic dy­s­tro­phy type 1 (DM1) out­side of the US while …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Ar­genx re­ports Vyv­gart sales streak, bol­stered by launch in rare neu­ro dis­or­der

Ab­b­Vie adds to T cell en­gager mo­men­tum, with EvolveIm­mune pact start­ing at $65M

Com­pass Path­ways de­lays key Phase 3 psilo­cy­bin read­outs, spurring 30% lay­offs

Am­gen makes pipeline cuts, but obe­si­ty plans re­main the fo­cus

Take­da says mul­ti­year re­struc­tur­ing is 'on track'

Evom­mune rais­es $115M for I&I pipeline and pre­pares for Phase 2 re­sults

A service from the Financial Times